Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

COVID-19 reinfection after pregnancy

L. Gobin a, A. Vallée a,*, D. Zucman b, M. Carbonnel c, J. Laperrelle c, O. Brugiére d, A. Martin a, J.-M. Ayoubi c, E. Farfour b

a Department of Clinical Research and Innovation, Foch Hospital, Suresnes, France
b Internal Medicine, Foch Hospital, Suresnes, France
c Department of Obstetrics Gynecology and Reproductive Medicine, Foch Hospital, Suresnes, France
d Lung Transplant Center and Center of Expertise for Cystic Fibrosis, Foch Hospital, Suresnes, France

A R T I C L E   I N F O
Article history:
Received 27 September 2021
Received in revised form 24 December 2021
Accepted 10 January 2022
Available online 20 January 2022

A B S T R A C T

Background: There have been reports of COVID-19 reinfections, but the immunological characterization of these cases is partial. We report a case of reinfection with SARS-CoV-2, where the first infection occurred in the course of late pregnancy.

Case presentation: On May 27, 2020, a 37-year-old woman gave birth at full term, 3 hours after full dilatation. She developed fever (38.3 °C) after delivery. Mild biological anomalies compatible with COVID-19 were observed: lymphopenia, thrombocytopenia, elevated D-Dimers, CRP, and LDH. At 6-month follow-up, she reported having contracted COVID-19 with high fever, rhinorrhea, hand frobites, cough, headache, dysgeusia and anosmia.

Conclusions: We report a case of COVID-19 reinfection with a first mild infection during late pregnancy and a more aggressive second infection 5 months later.

1. Background

The SARS-CoV-2 virus is the third known coronavirus after SARS-CoV and MERS-CoV. It was identified on January 9, 2020 and is responsible for severe lung damage with pneumonia in humans. For some viruses, the first infection can provide lifelong immunity; for seasonal coronaviruses, protective immunity is short-lived [1]. Duration of protection after COVID-19 is unknown and correlates of protection after SARS-CoV-2 vaccination need to be defined. There have been reports of COVID-19 reinfections, but the immunological characterization of these cases is partial [2]. The role of protective antibodies is probably essential, but protective cellular immunity could also play a role.

COVID-19 and acute respiratory distress syndromes (ARDS) are both characterized by an exacerbated inflammatory response related to macrophage activation syndrome and the ensuing “cytokine storm”. For ARDS, the viral load does not correlate with worsening clinical signs [3]. A dual therapeutic approach (antiviral and anti-inflammatory) has been proposed [4]. Due to the exacerbated inflammatory response to the virus, it is necessary to better understand the various cellular pathways leading to this immune response dysregulation. Among the immunological checkpoints of the immune response, the HLA-G molecule – a non-classic HLA class 1 molecule – is a well-known checkpoint [5] for its tolerogenic role, initially described for fetal-maternal tolerance [6]. We report a case of reinfection with SARS-CoV-2, where the first infection occurred during the course of late pregnancy.

2. Case presentation

On May 27, 2020, a 37-year-old woman gave birth at full term in our facility, 3 hours after full dilatation. She developed fever (38.3 °C) 2 hours after delivery. She had no comorbidity related to severe COVID-19 infection such as obesity, diabetes, or hypertension. The patient carried heterozygous Factor V Leiden mutation and had a family history of thromboembolism carrier and had received low-molecular-weight heparin prophylaxis (enoxaparin sodium) from 30 weeks of amenorrhea onwards. She also received valaciclovir from 36 weeks up until delivery for herpes recurrence during pregnancy.

In line with the recommendations, a nasopharyngeal SARS-CoV-2 RT-PCR test (Allplex2019-nCoV, Seegene, Seoul South Korea) was immediately performed and returned positive. The patient developed no other symptom subsequently, and fever disappeared. Blood oxygen saturation was 99% while breathing ambient air. Mild biological anomalies compatible with COVID-19 were present:
lymphopenia, thrombocytopenia and elevated D-Dimers, CRP and LDH (Table 1).

On May 30, 2020, the anti-SARS-CoV-2 IgG test (Abbott) was negative. Negative anti-SARS-CoV-2 IgG was confirmed 4 months later on September 29 by Roche Cobas® 6,000 diagnostic test (IgG index: 0.07).

At 6-month follow-up, the patient reported having contracted COVID-19, with symptoms from November 8 to 15, 2020 (high fever, rhinorrhea, hand frostbites, cough, headache, dysgeusia, and anosmia). She had a positive RT-PCR test on November 9 (SARS-CoV-2 multiple, Eurobio Serological). Serology for SARS-CoV-2 was strongly positive on December 7, 2020 by Roche electrochemiluminescence diagnostic test with total antibody index at 86.3 (negative < 1.00).

3. Discussion and conclusions

We report a case of COVID-19 reinfection with a first mild infection during late pregnancy and a more aggressive second infection 5 months later. Both episodes of COVID-19 were confirmed by positive nasopharyngeal RT-PCR tests.

The only signs of the first infection were brief acute moderate fever and mild blood test anomalies. Pregnant patients present with the same clinical characteristics of COVID-19 as the general population, but they may be more often asymptomatic [7]. This pauci-symptomatic COVID-19 case would not have been diagnosed if it were not for the systematic screening of febrile patients implemented during the first epidemic wave in France.

Fever is a frequent condition in postpartum women especially with long delivery.

A meta-analysis covering 10,491 patients suggested that CRP, PCT, LDH, and D-dimer could be early biomarkers of COVID-19 severity [8].

Elevated D-dimer concentrations usually reflect active coagulation and fibrinolysis, especially in case of COVID-19 infection during late pregnancy [9]. In our case, this condition could be linked to the heparin therapy received at the same time as the SARS-CoV-2 infection [9]. Indeed, D-dimer concentrations exponentially increase in pregnant women receiving heparin, peaking at the time of delivery [10].

Similarly, the increased CRP level observed in our patient after delivery may not be specific of SARS-CoV-2 viral infection; nevertheless, the rate observed in our patient is much higher than those reported by Mertens (around 10 mg/L) [11].

If recent data seem to show a low risk of maternalfetal transmission for the fetus [12], more severe cases of COVID-19 were described during the third trimester of pregnancy with a higher risk of ARDS, cesarean section [13], and premature birth [14]. The pathogenic thrombotic consequences of SARS-CoV-2 infection may threaten the pregnancy with maternal increase risk of thrombosis, intrauterine growth retardation, preeclampsia, and placenta thrombosis [13]. In our case, the use of low-molecular-weight heparin prophylaxis, administered for another reason, may have improved the outcome of the patient and her baby.

Titters, evolution, and the protective role of antibodies against SARS-CoV-2 reinfection are subjects to fierce debate. After mild or asymptomatic infection, low or undetectable titters or antibodies have been reported [15]. Recent data showed only 4.7% of positive anti-SARS-CoV-2-IgG antibodies among 529 pregnant patients systematically tested during labor between April and June 2020 in Paris [16]. Our patient’s serological tests performed in May and September were indeed both negative, but SARS-CoV-2 serology was strongly positive after the second COVID-19 episode. Similar cases have been reported [17]. A negative serology three days after delivery could be associated with infection that occurred several days or weeks before, with an unrelated fever during delivery, or could be related to the pregnancy-related immunodeficiency.

Persistent or fluctuant expression of SARS-CoV-2 RNA in the oropharyngeal swab test was reported, but this was reported in case of severe clinical symptoms or immunosuppressive conditions [2].

A few papers reported reinfection with SARS-CoV-2, but none related to a first episode occurring in a pregnant patient. Modulation of the maternal immune system during pregnancy and hormonal variations may affect the response to various infections, and more specifically to viruses. These alterations could be mediated in part by a decreased antibody level and could explain the negative serology after the first episode, contrasting with the strongly positive test after the second episode [18].

However, reinfection due to a variant viral strain could be a possibility as numerous new and more aggressive variants are described [19]. Several cases of reinfection were fully documented, but with respect to the millions of infected patients, those cases are rare. Selvaraj [20] described a clinical case of severe symptomatic reinfection and presented a summary of reported reinfection cases. He stated that there is an apparent paradox between declining antibody levels and low incidence of reinfection, implying that other immune mechanisms are at work, including T lymphocytes. Our case questions pregnancy as inhibitor of antibody production. To our knowledge, it is the first case of reinfection after pregnancy. The role of HLA-G immuno-inhibitor may be questioned and may be a possible treatment.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the 1964 Helsinki declaration and its later amendments.

Contribution of authors

AL, AV, and DZ wrote the article. MC, JL, OB, AM, JMA, and EF contributed to re-writing the article. All authors read and approved the definitive version of the manuscript.
Funding

None.

Disclosure of interest

The authors declare that they have no competing interest.

Acknowledgments

Not applicable.

References

[1] Edridge AWD, Kaczorowska J, Hoste ACR, Bakker M, Klein M, Loens K, et al. Seasonal coronavirus protective immunity is short-lasting. Nat Med 2020;26:1691–3, http://dx.doi.org/10.1038/s41591-020-1083-1.
[2] Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. Recurrence of positive SARS-CoV-2 RNA in COVID-19: a case report. Int J Infect Dis 2020;93:297–9, http://dx.doi.org/10.1016/j.ijid.2020.03.003.
[3] Roumier M, Paule R, Vallée A, Rohmer J, Ballester M, Bru occultum for severe worsening COVID-19 pneumonia: a propensity score analysis. J Clin Immunol 2020, http://dx.doi.org/10.1007/s10875-020-00911-6.
[4] Stebbing J, Phelan A, Griffin I, Tucker C, Oechele O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis 2020;20:400–2, http://dx.doi.org/10.1016/S1473-3099(20)30132-8.
[5] Loustau M, Wiendl H, Ferrone S, Carosella ED. HLA-G 2012 conference: the 15-year milestone update. Tissue Antigens 2013;81:127–36, http://dx.doi.org/10.1111/tan.12053.
[6] Carosella ED, Favier B, Rouas-Freiss N, Moreau P, Lemaoult J. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008;111:4862–70, http://dx.doi.org/10.1182/blood-2007-12-127662.
[7] Jafari M, Pirmohammad A, Sheikh-Neshin SA, Chorbani S, Bose D, Alimohammad S, et al. Clinical characteristics and outcomes of pregnant women with COVID-19 and comparison with control patients: a systematic review and meta-analysis. Rev Med Virol 2021:e2208, http://dx.doi.org/10.1002/rmv.2208.
[8] Malik P, Patel U, Mehta D, Patel N, Kelkar R, Akrmah M, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis. BMJ Evid-Based Med 2020, http://dx.doi.org/10.1136/bmjebm-2020-111536 [bmjebm-2020-111536]
[9] Zhou J, Wang Y, Zhao J, Gu L, Yang C, Wang J, et al. The metabolic and immunological characteristics of pregnant women with COVID-19 and their neonates. Eur J Clin Microbiol Infect Dis 2021;40:565–74, http://dx.doi.org/10.1007/s10096-020-04033-0.
[10] Patel JP, Patel RK, Roberts LN, Marsh MS, Green B, Davies JG, et al. Changes in thrombin generation and D-dimer concentrations in women injecting enoxaparin during pregnancy and the puerperium. BMC Pregnancy Childbirth 2014;14, http://dx.doi.org/10.1186/s12884-014-0384-0.
[11] Mertens K, Muy J, Jakemym X. Postpartum C-reactive protein: a limited value to detect infection or inflammation. Facts Views Vis ObGyn 2015;11:243–50.
[12] Lu D, Sang L, Du S, Li T, Chang Y, Yang X-A. Asymptomatic COVID-19 infection in late pregnancy indicated no vertical transmission. J Med Virol 2020;92:1660–4, http://dx.doi.org/10.1002/jmv.25927.
[13] Antoun L, Taweel N, Ahmed I, Patni S, Honest H. Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcomes: a prospective cohort study. Eur J Obstet Gynecol Reprod Biol 2020;252:559–62, http://dx.doi.org/10.1016/j.ejogrb.2020.07.008.
[14] Kayem G, Lecarpentier E, Deruelle F, Bretelle F, Azria E, Blanc J, et al. A snapshot of the COVID-19 pandemic among pregnant women in France. J Gynecol Obstet Hum Reprod 2020;49:101826, http://dx.doi.org/10.1016/j.jogoh.2020.101826.
[15] Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody responses to SARS-CoV-2 in patients with novel Coronavirus Disease 2019. Clin Infect Dis 2021;71:2027–34, http://dx.doi.org/10.1093/cid/ciaa344.
[16] Tsatsaris V, Mariaggi A-A, Launay O, Couffignal C, Rousseau J, Ancel PY, et al. SARS-COV-2 IgG antibody response in pregnant women at delivery. J Gynecol Obstet Hum Reprod 2021;50:102041, http://dx.doi.org/10.1016/j.jogoh.2020.102041.
[17] Torres D, de A, Ribeiro L, do CB, Riello AP, de FL, et al. Reinfection of COVID-19 after 3 months with a distinct and more aggressive clinical presentation: case report. J Med Virol 2020, http://dx.doi.org/10.1002/jmv.25637.
[18] Alberca RW, Pereira NZ, Oliveira LMDS, Gozzi-Silva SC, Sato MN. Pregnancy, viral infection, and COVID-19. Front Immunol 2020;11, http://dx.doi.org/10.3389/fimmu.2020.01672.
[19] Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health 2021;6:e335–45, http://dx.doi.org/10.1016/S2468-2667(21)00055-4.
[20] Selvaraj V, Herman K, Dapaah-Afriey K. Severe, symptomatic reinfection in a patient with COVID-19. R I Med J 2020;103:24–6.